Under the agreement, GP Pharm will extend the manufacturing of Busulipo from clinical to commercial quantities, which is an important step in progressing the product towards the market.
Financial details of the deal have not been disclosed.
Pharmalink managing director Johan Haggblad said Busulipo is an immediate release liposome formulation that improves the safety and stability of the chemotherapy agent busulfan, a conditioning agent for use prior to hematopoietic stem cell transplantation (HSCT).
"Busulipo allows the elimination of the toxic solvent DMA and has been designed to have a two year shelf life and increased stability after reconstitution," Haggblad added.
"GP Pharm has an excellent track record in the manufacturing of complex injectables and specifically with liposomes.
"We look forward to working with GP Pharm as Busulipo enters the next phase of clinical development."